Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Design Therapeutics’ SEC filings can feel like a second language. When a single 10-K packs hundreds of pages on GeneTAC™ chemistry, clinical trial risk factors, and cash runway projections, finding the line items that move your model is tough. Add fast-moving 8-K updates on trial data and Form 4 insider trades as executives adjust exposure before milestones, and the research burden multiplies.
Our platform turns this complexity into clarity. Stock Titan’s AI parses every Design Therapeutics 10-K annual report, 10-Q quarterly earnings report, and 8-K material event in real time, surfaces R&D spend trends, flags dilution clauses, and translates technical gene-targeted-chimera language into everyday terms. Need to monitor Design Therapeutics insider trading Form 4 transactions? We deliver instant alerts on each filing, including Design Therapeutics executive stock transactions Form 4 with side-by-side historical context. Curious about pipeline progress? The AI highlights sections that disclose trial enrollment, FDA feedback, or next-step timelines so you can evaluate probability of success without combing footnotes.
Every document type is covered: 10-K risk factors for cash burn analysis, 10-Q updates on operating expenses, S-1 or 424B prospectuses for potential share offerings, 13D/G ownership shifts, and proxy statements that outline Design Therapeutics executive compensation. Whether you Google “Design Therapeutics SEC filings explained simply” or ask ChatGPT “How do I read Design Therapeutics’ earnings report filing analysis?”, this page delivers answers backed by AI-powered summaries, keyword search inside PDFs, and download-ready spreadsheets. Stay ahead with Design Therapeutics Form 4 insider transactions real-time, see the story behind each 8-K, and understand every footnote—without the late-night chase.
Justin D. Gover, a director of Design Therapeutics, Inc. (DSGN), reported two option grants dated 09/09/2025. The filing shows awards of 30,000 and 15,833 stock options with an exercise price of $6.64 each, representing 45,833 underlying shares in total. The reporting form lists these as direct holdings. The filing includes vesting schedules: the 30,000-option award vests in equal monthly installments over 36 months following September 9, 2025, and the 15,833-option award vests in equal monthly installments over 12 months following September 9, 2025. The form was signed on behalf of the reporting person on 09/10/2025.
Design Therapeutics, Inc. reported an initial Form 3 for director Justin D. Gover relating to an event on 09/09/2025. The filing states the reporting person is a Director and that no securities are beneficially owned by Mr. Gover as of the reporting date. The Form 3 was signed by an attorney-in-fact on 09/10/2025. The filing notifies investors that the director currently holds no direct or indirect equity in the issuer.
Point72 affiliates reported ownership of 2,942,719 shares of Design Therapeutics, Inc. (CUSIP 25056L103), representing 5.2% of the outstanding common stock as of the close of business on August 27, 2025. The filing states that Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. share voting and dispositive power over these shares, and that Steven A. Cohen exercises control of those entities. Point72 Associates is identified as the fund holding the shares and has the right to receive dividends or sale proceeds. The filing includes a joint filing agreement as Exhibit 99.1 and lists principal business and issuer addresses.
Design Therapeutics director William Arsani reported sales of company common stock on 08/13/2025. The Form 4 shows two dispositions executed at $5.25 per share: 345,000 shares sold by Logos Global Master Fund LP and 217,627 shares sold by Logos Opportunities Fund II LP. After the sales, the filing reports 2,655,000 shares beneficially owned by Logos Global Master Fund LP and 1,000,000 shares beneficially owned by Logos Opportunities Fund II LP. Arsani is identified as a director and the filing disclaims direct beneficial ownership except to the extent of a pecuniary interest through the reported funds. The form is signed by an attorney-in-fact on 08/14/2025.
Design Therapeutics reported a Form 144 notice proposing the sale of 217,627 common shares, with an aggregate market value of $1,083,783.00, scheduled approximately for 08/13/2025 on NASDAQ through broker BTIG, LLC. The filing shows the shares were originally acquired on 01/25/2021 in a private market transaction from Design Therapeutics, with 1,984,733 shares acquired and paid in cash on that date. The filer reports no securities sold in the past three months and affirms they are unaware of any undisclosed material adverse information about the issuer.
Design Therapeutics filed a Form 144 reporting a proposed sale of 345,000 common shares through BTIG, LLC with an aggregate market value of $1,718,100.00. The filing lists 56,900,000 shares outstanding and shows the shares were acquired on 03/26/2021 in the open market (700,000 acquired) with cash payment.
The Form 144 indicates an approximate sale date of 08/13/2025, notes nothing to report for securities sold in the past three months, and includes the filers representation that they are not aware of any undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Design Therapeutics (DSGN)?
What is the market cap of Design Therapeutics (DSGN)?
